Icon

IDHIFA - (50MG, 100MG)

ENASIDENIB MESYLATE None
50MG, 100MG
Less Than $1000 mn
None None
None None
None None
IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Yes
IDHIFA Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
*** *********

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.